Rösch, L., Herter, S., Najafi, S., Ridinger, J., Peterziel, H., Cinatl, J., Jones, D.T.W., Michaelis, M., Witt, O., Oehme, I. (2022) ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Molecular Oncology. 17(1):37-58
|
Anderson, N.M., Qin, X., Finan, J.M., Lam, A., Athoe, J., Missiaen, R., Skuli, N., Kennedy, A., Saini, A.S., Tao, T., Zhu, S., Nissim, I., Look, A.T., Qing, G., Simon, M.C., Feng, H. (2021) Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma. Cancer research. 81(17):4417-4430
|
Cheung, B.B., Kleynhans, A., Mittra, R., Kim, P.Y., Holien, J.K., Nagy, Z., Ciampa, O.C., Seneviratne, J.A., Mayoh, C., Raipuria, M., Gadde, S., Massudi, H., Wong, I.P.L., Tan, O., Gong, A., Suryano, A., Diakiw, S.M., Liu, B., Arndt, G.M., Liu, T., Kumar, N., Sangfelt, O., Zhu, S., Norris, M.D., Haber, M., Carter, D.R., Parker, M.W., Marshall, G.M. (2021) A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. Oncogene. 40(13):2367-2381
|
Dong, Z., Yeo, K.S., Lopez, G., Zhang, C., Dankert Eggum, E.N., Rokita, J.L., Ung, C.Y., Levee, T.M., Her, Z.P., Howe, C.J., Hou, X., van Ree, J.H., Li, S., He, S., Tao, T., Fritchie, K., Torres-Mora, J., Lehman, J.S., Meves, A., Razidlo, G.L., Rathi, K.S., Weroha, S.J., Look, A.T., van Deursen, J.M., Li, H., Westendorf, J.J., Maris, J.M., Zhu, S. (2021) GAS7 Deficiency Promotes Metastasis in MYCN-driven Neuroblastoma. Cancer research. 81(11):2995-3007
|
Körholz, K., Ridinger, J., Krunic, D., Najafi, S., Gerloff, X.F., Frese, K., Meder, B., Peterziel, H., Vega-Rubin-de-Celis, S., Witt, O., Oehme, I. (2021) Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma. Cells. 10(5)
|
Almstedt, E., Elgendy, R., Hekmati, N., Rosén, E., Wärn, C., Olsen, T.K., Dyberg, C., Doroszko, M., Larsson, I., Sundström, A., Arsenian Henriksson, M., Påhlman, S., Bexell, D., Vanlandewijck, M., Kogner, P., Jörnsten, R., Krona, C., Nelander, S. (2020) Integrative discovery of treatments for high-risk neuroblastoma. Nature communications. 11:71
|
Shi, H., Tao, T., Abraham, B.J., Durbin, A.D., Zimmerman, M.W., Kadoch, C., Look, A.T. (2020) ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Science advances. 6:eaaz3440
|
Tao, T., Shi, H., Wang, M., Perez-Atayde, A.R., London, W.B., Gutierrez, A., Lemos, B., Durbin, A.D., Look, A.T. (2020) Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. The Journal of experimental medicine. 217(10):
|
Corallo, D., Donadon, M., Pantile, M., Sidarovich, V., Cocchi, S., Ori, M., De Sarlo, M., Candiani, S., Frasson, C., Distel, M., Quattrone, A., Zanon, C., Basso, G., Tonini, G.P., Aveic, S. (2019) LIN28B increases neural crest cell migration and leads to transformation of trunk sympathoadrenal precursors. Cell death and differentiation. 27(4):1225-1242
|
Koach, J., Holien, J.K., Massudi, H., Carter, D.R., Ciampa, O.C., Herath, M., Lim, T., Seneviratne, J.A., Milazzo, G., Murray, J.E., McCarroll, J.A., Liu, B., Mayoh, C., Keenan, B., Stevenson, B.W., Gorman, M.A., Bell, J.L., Doughty, L., Hüttelmaier, S., Oberthuer, A., Fischer, M., Gifford, A.J., Liu, T., Zhang, X., Zhu, S., Gustafson, W.C., Haber, M., Norris, M.D., Fletcher, J.I., Perini, G., Parker, M.W., Cheung, B.B., Marshall, G.M. (2019) Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. Cancer research. 79:5652-5667
|
Fadeev, A., Mendoza-Garcia, P., Irion, U., Guan, J., Pfeifer, K., Wiessner, S., Serluca, F., Singh, A.P., Nüsslein-Volhard, C., Palmer, R.H. (2018) ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells. Proceedings of the National Academy of Sciences of the United States of America. 115(4):E630-E638
|
Shen, J., Najafi, S., Stäble, S., Fabian, J., Koeneke, E., Kolbinger, F.R., Wrobel, J.K., Meder, B., Distel, M., Heimburg, T., Sippl, W., Jung, M., Peterziel, H., Kranz, D., Boutros, M., Westermann, F., Witt, O., Oehme, I. (2018) A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Cell death and differentiation. 25(12):2053-2070
|
Aveic, S., Corallo, D., Porcù, E., Pantile, M., Boso, D., Zanon, C., Viola, G., Sidarovich, V., Mariotto, E., Quattrone, A., Basso, G., Tonini, G.P. (2017) TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy. European Journal of Pharmacology. 818:435-448
|
Radic-Sarikas, B., Halasz, M., Huber, K.V.M., Winter, G.E., Tsafou, K.P., Papamarkou, T., Brunak, S., Kolch, W., Superti-Furga, G. (2017) Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Scientific Reports. 7:3091
|
Tao, T., Sondalle, S.B., Shi, H., Zhu, S., Perez-Atayde, A.R., Peng, J., Baserga, S.J., Look, A.T. (2017) The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma. Oncogene. 36(27):3852-3867
|
Zhang, X., Dong, Z., Zhang, C., Ung, C.Y., He, S., Tao, T., Oliveira, A.M., Meves, A., Ji, B., Look, A.T., Li, H., Neel, B.G., Zhu, S. (2017) Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Reports. 18:2932-2942
|
Zhu, S., Zhang, X., Weichert-Leahey, N., Dong, Z., Zhang, C., Lopez, G., Tao, T., He, S., Wood, A.C., Oldridge, D., Ung, C.Y., van Ree, J.H., Khan, A., Salazar, B.M., Lummertz da Rocha, E., Zimmerman, M.W., Guo, F., Cao, H., Hou, X., Weroha, S.J., Perez-Atayde, A.R., Neuberg, D.S., Meves, A., McNiven, M.A., van Deursen, J.M., Li, H., Maris, J.M., Look, A.T. (2017) LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell. 32(3):310-323.e5
|
He, S., Mansour, M.R., Zimmerman, M.W., Ki, D.H., Layden, H.M., Akahane, K., Gjini, E., de Groh, E.D., Perez-Atayde, A.R., Zhu, S., Epstein, J.A., Look, A.T. (2016) Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. eLIFE. 5
|
Fey, D., Halasz, M., Dreidax, D., Kennedy, S.P., Hastings, J.F., Rauch, N., Munoz, A.G., Pilkington, R., Fischer, M., Westermann, F., Kolch, W., Kholodenko, B.N., Croucher, D.R. (2015) Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Science signaling. 8:ra130
|
|
|
Pei, D., Luther, W., Wang, W., Paw, B.H., Stewart, R.A., and George, R.E. (2013) Distinct Neuroblastoma-associated Alterations of PHOX2B Impair Sympathetic Neuronal Differentiation in Zebrafish Models. PLoS Genetics. 9(6):e1003533
|
Zhu, S., Lee, J.S., Guo, F., Shin, J., Perez-Atayde, A.R., Kutok, J.L., Rodig, S.J., Neuberg, D.S., Helman, D., Feng, H., Stewart, R.A., Wang, W., George, R.E., Kanki, J.P., and Look, A.T. (2012) Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. Cancer Cell. 21(3):362-373
|
